CTOs on the Move


 
Foria is an innovative health & sexual wellness company, rooted in the proven wisdom of plants and powered by compassion. Our all natural Cannabis & Hemp formulas have been changing lives since 2014. As the first brand to create comprehensive product lines for intimacy, relief, and optimal wellbeing for women and people with vulvas, it is our joy and mission to offer effective products for important and under-served life experiences. With an unwavering commitment to clean ingredients, organic & regenerative farming, sex education, and responsible packaging, we maintain the highest standards of purity and transparency — for your health, ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Repertoire

Repertoire Immune Medicines is working to unleash the remarkable power of the human immune system to prevent, treat or cure cancer, autoimmune conditions, and infectious diseases. Repertoire scientists created and developed a suite of technologies for its DECODE discovery and DEPLOY product platforms that allow in-depth characterization of the immune synapse and the ability to rationally design, and clinically develop, multi-clonal immune medicines. The company is currently conducting experimental medicine clinical trials using autologous T cells primed against cancer antigens and tethered to IL-15.

Parata Systems

Parata Systems is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Durham, NC. To find more information about Parata Systems, please visit www.parata.com

Elementis Specialties (RHEOX)

Elementis Specialties (RHEOX) is a Hightstown, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Blue River PetCare

we can help Selling your Veterinary clinic with the help of Blue River Pet Care. Receive a Veterinary Practice Valuation. We acquire veterinary hospitals that provide high-quality clinical care and leading rate customer service.

Acucela

Acucela is a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases impacting millions of individuals worldwide. Acucela currently has the following candidates in development with Otsuka Pharmaceutical: emixustat hydrochloride for GA associated with dry AMD based on Acucela’s proprietary visual cycle modulation; and OPA-6566 for ocular hypertension and glaucoma.